Literature DB >> 28775203

Immunohistochemical Validation of PSMA Expression Measured by 68Ga-PSMA PET/CT in Primary Prostate Cancer.

Nadine Woythal1, Ruza Arsenic2, Carsten Kempkensteffen3, Kurt Miller4, Jan-Carlo Janssen5, Kai Huang1, Marcus R Makowski5, Winfried Brenner1, Vikas Prasad6.   

Abstract

68Ga-labeled prostate-specific membrane antigen (68Ga-PSMA) PET/CT has a proven role in staging and restaging of prostate cancer (PCA). The aims of this study were to evaluate the association of intraprostatic 68Ga-PSMA PET/CT findings and PSMA expression in immunohistochemical staining and generate a cutoff value for differentiation between normal prostate (PN) and PCA.
Methods: The data of 31 patients (mean age, 67.2 y) who underwent prostatectomy and preoperative PET were retrospectively analyzed. On PET, focally increased uptake in the prostate was suggestive of tumor. A region of interest was placed on the suggestive area to generate an SUVmax; a similar region of interest was placed on adjacent visually PN. Both PCA and PN were stained with monoclonal anti-PSMA antibody (clone 3E6, 1:100, M3620).
Results: All intraprostatic PCA lesions on PET could be confirmed histopathologically. In PN sections (n = 31), median staining intensity was mild, median percentage of stained cells was 20% ± 14.24%, and median immunoreactive score (IRS) was 1. In PCA sections (n = 31), median IRS was 3, median staining intensity was strong, and median percentage of stained cells was 80% ± 16.46%. The mean SUVmax (±SD) of PCA (14.06 ± 15.56) was significantly higher than that of PN (2.43 ± 0.63; P < 0.001). Receiver-operating-characteristic curve analyses of the SUVmax of PCA, validated by immunohistochemical staining in 62 tissue samples, showed the best cutoff to be 3.15 (sensitivity, 97%; specificity, 90%; area under curve, 0.987). Applied to multifocal PCA, it resulted in sensitivity and specificity of 87% and 97% respectively. The mean SUVmax of PCA and PN for an IRS of less than 2 (n = 26; 2.52 ± 0.64) was significantly lower than the mean SUVmax for an IRS of 2 or more (n = 36; 12.38 ± 15.02; P < 0.001). The mean SUVmax was significantly lower in PCA samples with fewer than 50% stained cells (n = 30; 2.81 ± 2.35) than in samples with 50% or more (n = 32; 13.34 ± 15.55; P < 0.001). There was no correlation between the SUVmax of PCA and Gleason score (P = 0.54).
Conclusion: This study showed that SUVmax on 68Ga-PSMA PET/CT correlates significantly with PSMA expression in primary PCA, enabling the detection of PCA with a high sensitivity and specificity.
© 2018 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  68Ga-PSMA PET/CT; SUVmax cutoff; immunohistochemistry; prostate cancer; prostate specific membrane antigen

Mesh:

Substances:

Year:  2017        PMID: 28775203     DOI: 10.2967/jnumed.117.195172

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  44 in total

1.  Quantitative characterisation of clinically significant intra-prostatic cancer by prostate-specific membrane antigen (PSMA) expression and cell density on PSMA-11.

Authors:  Liran Domachevsky; Natalia Goldberg; Hanna Bernstine; Meital Nidam; David Groshar
Journal:  Eur Radiol       Date:  2018-05-30       Impact factor: 5.315

2.  Diagnostic performance of 68Ga-PSMA PET/CT for identification of aggressive cribriform morphology in prostate cancer with whole-mount sections.

Authors:  Jie Gao; Chengwei Zhang; Qing Zhang; Yao Fu; Xiaozhi Zhao; Mengxia Chen; Bing Zhang; Danyan Li; Jiong Shi; Feng Wang; Hongqian Guo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-04-25       Impact factor: 9.236

3.  [68Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review.

Authors:  Frédéric Bois; Camille Noirot; Sébastien Dietemann; Ismini C Mainta; Thomas Zilli; Valentina Garibotto; Martin A Walter
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-12-15

Review 4.  Advances in prostate-specific membrane antigen PET of prostate cancer.

Authors:  Kirsten Bouchelouche; Peter L Choyke
Journal:  Curr Opin Oncol       Date:  2018-05       Impact factor: 3.645

5.  18F-PSMA-1007 multiparametric, dynamic PET/CT in biochemical relapse and progression of prostate cancer.

Authors:  Christos Sachpekidis; A Afshar-Oromieh; K Kopka; D S Strauss; L Pan; U Haberkorn; A Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-14       Impact factor: 9.236

6.  Improved specificity with 68Ga PSMA PET/CT to detect clinically significant lesions "invisible" on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology.

Authors:  Peter Donato; Matthew J Roberts; Andrew Morton; Samuel Kyle; Geoff Coughlin; Rachel Esler; Nigel Dunglison; Robert A Gardiner; John Yaxley
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-19       Impact factor: 9.236

7.  Diagnostic Accuracy of 68Ga-PSMA-11 PET/MRI Compared with Multiparametric MRI in the Detection of Prostate Cancer.

Authors:  Robert M Hicks; Jeffry P Simko; Antonio C Westphalen; Hao G Nguyen; Kirsten L Greene; Li Zhang; Peter R Carroll; Thomas A Hope
Journal:  Radiology       Date:  2018-09-18       Impact factor: 11.105

8.  Dynamic patterns of [68Ga]Ga-PSMA-11 uptake in recurrent prostate cancer lesions.

Authors:  Ian Alberts; Christos Sachpekidis; Eleni Gourni; Silvan Boxler; Tobias Gross; George Thalmann; Kambiz Rahbar; Axel Rominger; Ali Afshar-Oromieh
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-10-18       Impact factor: 9.236

9.  Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer.

Authors:  Bobby Shaygan; Katherine Zukotynski; François Bénard; Cynthia Ménard; Joda Kuk; Golmehr Sistani; Glenn Bauman; Patrick Veit-Haibach; Ur Metser
Journal:  Can Urol Assoc J       Date:  2021-06       Impact factor: 1.862

10.  Optimized Application of 68Ga-Prostate-Specific Membrane Antigen-617 Whole-Body PET/CT and Pelvic PET/MR in Prostate Cancer Initial Diagnosis and Staging.

Authors:  Chunxia Qin; Yongkang Gai; Qingyao Liu; Weiwei Ruan; Fang Liu; Fan Hu; Xiaoping Zhang; Xiaoli Lan
Journal:  Front Med (Lausanne)       Date:  2021-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.